Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Nova Wellness has solid fundamentals with consistent profit margins and low debt, making it a reliable pick for the long-term dividend investor. Don't be distracted by the election noise, because their business model is built to sustain growth regardless of who sits in the parliament.
Duopharma’s strong market position in the generic drug sector offers steady long-term growth, but current valuations look a bit pricey for the modest earnings recovery. You need to wait for a better entry point because the margins are quite tight given the intense competition in the pharmaceutical space.
Kotra’s export diversification across ASEAN and beyond provides a solid buffer against US tariffs, while their 70% domestic exposure helps stabilize earnings. As long as the USD remains manageable for their raw material imports, the business fundamentals look steady for long-term compounding.
Pharmaniaga's financials are still messy with that massive PN17 hit, and until their balance sheet clears up, the fundamentals remain very shaky for long-term holding. 18-19 cents is just a psychological resistance; until they actually show sustainable profit growth, better to wait on the sidelines.
With their focus on affordable housing, the margins are tight but the demand is super resilient for the long haul. If they keep managing their debt well like this, the valuation remains attractive for investors looking to hold for a few cycles.
Datacenter demand confirm steady but you need prepare mental for the crazy swing if want hold long term. Once more renewable energy deal come in, this stock sure rally kaw kaw one.
